SOARING HEALTH

07/27/2026

Regulators are asking a different question about real-world evidence now, and most organizations aren't prepared for it. Jennifer Webster from Pfizer's RWE Platforms team mentioned something that stuck with me: the conversation has shifted from "Do you have RWD?" to "Do you understand the provenance of the data? Have you validated your endpoints and covariates?"

That's not a small semantic shift. That's the entire foundation of your evidence strategy getting reexamined. I think about this when I'm working with biotech partners on market access planning. Teams often want to layer RWE on top of clinical data as a supporting narrative. But if regulators and payers are now demanding proof of clinical correlation and data lineage upfront, you can't retrofit rigor into your evidence plan. You need to bake it in from the beginning.

The organizations moving fastest aren't the ones collecting more data. They're the ones designing their evidence strategies around what will actually satisfy regulatory scrutiny and payer decision-making six months from now, not just what looks good today. What's your approach to demonstrating data provenance in your evidence submissions? Are you treating it as a checkbox or a strategic priority?

Pfizer partnered with Premier Applied Sciences to raise the bar for real-world evidence (RWE) as an engine for quality, credibility and impact in regulatory and scientific decision-making.

07/24/2026

Randomized clinical trials still cost roughly 40% of the pharmaceutical industry's R&D budget in the US. They're essential. They're also increasingly insufficient on their own. Why? Because a trial tells you how a therapy performs in a controlled population.

Real-world evidence tells you how it performs in actual practice, across different comorbidities, drug interactions, social circumstances, and patient behaviors that clinical trials deliberately exclude.

The market is already reflecting this shift. The pharmaceutical and life sciences RWE market is projected to grow from $3.57 billion in 2026 to $5.6 billion by 2030, driven largely by payers and health systems demanding evidence that actually predicts real-world outcomes.

For HEOR teams and market access strategists, the implication is clear: your competitive edge isn't in collecting more data. It's in building the infrastructure to turn messy, complex real-world data into decision-ready evidence that physicians and regulators genuinely trust. That infrastructure doesn't exist in most organizations yet. This seems to be an opportunity.

The Pharmaceutical and Life Sciences Real World Evidence Market, valued at USD 3.57B in 2026, is projected to reach USD 5.6B by 2030, growing at a 11.9% CAGR.

07/21/2026

Real-world evidence has moved from speculative to operational. The FDA's case studies now show RWE supporting approval decisions, labeling expansions, and risk-benefit assessments across oncology, rare disease, and other therapeutic areas. The EMA expanded DARWIN EU to 30 partners covering 180 million patients. Japan's PMDA accepts RWE for external control arms in orphan drug approvals.

What's striking is how quietly this happened. There's been minimal industry discussion despite the fact that regulatory inflection points like this are exactly what shape market access strategy for the next five years.

For payers and market access teams, this signals a shift in what evidence payers will demand and what regulators will accept. The clinical trial versus real-world gap is narrowing at the regulatory level, which means the evidence you generate for reimbursement conversations needs to reflect that rigor. You can't rely on RWE as a secondary narrative anymore. It's becoming primary. The teams building evidence infrastructure now have a structural advantage.

https://www.adnovateclinical.com/news/regulatoryacceptanceofrealworldevidence2026/

07/16/2026

The FDA just removed a longstanding requirement that real-world evidence in drug and device applications include identifiable patient data. That's not a procedural change. That's a signal.

For years, regulatory agencies treated RWE like an afterthought. Now it's central to how they evaluate safety, effectiveness, and new indications. The 21st Century Cures Act opened the door. PDUFA VII formalized it. Regulatory bodies globally are issuing guidance, conducting pilots, and actively facilitating RWE use in submissions and post-market evaluations.

What does this mean for your organization? If you've been hesitating on RWE strategy because of regulatory uncertainty, that's disappearing. If you're still treating RWE as supplementary to trial data, you're behind. If you're not building evidence generation into your product lifecycle from development through post-approval, you're leaving value on the table.

The infrastructure for defensible, decision-grade RWE is here. The regulatory acceptance is here. The question now is ex*****on.

Real world evidence solutions market size was valued at $3.0B in 2025 and is projected to grow from $3.3B in 2026 to $6.0B by 2033, at a CAGR of 9.1%

07/14/2026

TriNetX just launched a conversational AI interface in January 2026 that lets you query their federated RWD network in plain English instead of SQL. Meanwhile, EMA's DARWIN, EU network now spans 32 data partners and 180 million patients across Europe, with a competitive tender set for H1 2026 to extend the program through 2032.

The infrastructure is finally scaling. But here's what I keep seeing: companies have access to more data sources than ever. The constraint isn't data anymore. It's translating what's in those networks into evidence that regulators, payers, and health systems actually trust and act on.

Generating RWD at scale is one problem. Generating *defensible* RWE that moves reimbursement decisions or label expansion discussions is another. The teams investing now aren't just building data pipelines. They're building the methodological rigor and stakeholder alignment that turns data access into evidence adoption.

Explore the state of Real-World Evidence (RWE) analysis in 2025-2026. This guide covers RWD sources, analytical methods, FDA/EMA regulatory frameworks, ICH E6(R3), synthetic control arms, AI-driven RWE platforms, and compares RWE with RCTs

07/09/2026

Real-world evidence frameworks are finally moving from regulatory nice-to-have to actual decision-making infrastructure. The UK's MHRA is leading this shift, and the FDA's embrace of target trial emulation signals where the rest of the world is heading.

What struck me reviewing recent submissions across North America, Europe, and Australia: explicit regulatory endorsement for RWE studies appears in only about 30% of approvals. The infrastructure exists. The methods are there. But alignment between what manufacturers submit and what agencies actually find credible remains fragmented.

For outcomes researchers and health economists, this means your next RWE strategy can't be generic. It needs to reflect the specific decision context. Oncology requires a different rigor than rare disease. A payer negotiation needs different evidence than a regulatory submission.

The teams winning right now aren't the ones with the most data. They're the ones translating data into evidence that matches how each decision-maker actually thinks.

The integration of clinical and real-world evidence represents one of the most critical transformations in modern drug development and health technology asse...

07/07/2026

Most pharma teams still treat RWE as a post-approval activity. Audit the data, satisfy a regulatory requirement, move on. But organizations building institutional maturity around real-world evidence are doing something different entirely.

They're baking evidence generation into development strategy from day one. Clinical protocol design. Trial site selection. Patient cohort definition. Registry infrastructure. They're asking how RWD can compress timelines and reduce uncertainty before they even submit to regulators.

The shift is material. One RWE-forward program reduced planned sample size by 40% in a Phase III trial, translating to six months of time savings. That's not incremental. That's structural advantage.

The constraint isn't data access anymore. Claims databases, EHRs, registries, digital health streams- the infrastructure exists. The organizations pulling ahead are the ones building internal capability to frame decisions, relevant questions, generate defensible analyses, and actually move decisions based on findings.

That requires more than acquiring data assets. It requires integrated teams, analytical rigor, and a product lifecycle perspective. The competitive edge belongs to those who can turn data into trusted, repeatable, decision-ready evidence.

How is your organization approaching RWE strategy across development, regulatory, and market access?

Learn how companies that treat RWE as an operational capability will be better positioned to design more efficient trials, accelerate therapy adoption, strengthen payer negotiations, and demonstrate value across the healthcare ecosystem.

07/03/2026

Datavant's acquisition of Aetion in July 2025 created a 300+ data partner network accepted by both FDA and EMA. That's infrastructure. Tempus hit $1.1B in total contract value by December 2025. The RWE consolidation wave isn't about collecting more data. It's about building platforms that can move evidence faster, across borders, and into decisions that actually matter.

What that means for pharmaceutical teams: outsourcing data analytics is no longer optional. The competitive landscape is shifting toward companies with real-world evidence capabilities embedded in their operations, not bolted on afterward. Your evidence strategy needs to match the speed of the market.

Explore the state of Real-World Evidence (RWE) analysis in 2025-2026. This guide covers RWD sources, analytical methods, FDA/EMA regulatory frameworks, ICH E6(R3), synthetic control arms, AI-driven RWE platforms, and compares RWE with RCTs

06/26/2026

The FDA just updated its RWE guidance for medical devices in December 2025, and the signal is unmistakable: real-world evidence is no longer optional in regulatory decision-making. But here's what's been nagging at me. We've known for years that RCTs don't capture the full patient picture. A 65, year, old managing diabetes, hypertension, and depression while taking five medications? They're rarely in your perfectly controlled trial. Yet we keep treating RCT data as the gold standard and RWE as the backup plan.

The FDA's expanded guidance now explicitly supports using RWE as primary evidence in premarket submissions. That's not incremental. That's a fundamental shift in how we validate whether therapies actually work for the people who need them.

For HEOR and market access teams, this means the infrastructure you build today around claims data, EHR analytics, and patient registries isn't just nice to have. It's becoming table stakes for regulatory strategy.

What's your team doing to integrate RWE into your evidence generation roadmap?

The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance entitled "Use of Real- World Evidence to Support Regulatory Decision-Making for Medical Devices." FDA is issuing this guidance to clarify how FDA evaluates real-world data (RWD) to...

06/24/2026

80% of payers want to use real-world evidence in their reimbursement decisions. Only 18% actually do. The gap isn't about data availability. Manufacturers are generating RWE. The problem is structural: payers lack the frameworks to evaluate it, regulators apply inconsistent standards, and clinical teams design evidence packages without knowing what market access actually needs.

This is the friction point where evidence stalls. A well-designed RWE package that impresses the FDA can sit on a payer's desk because it doesn't answer their specific economic questions. A health economics analysis that's methodologically sound still fails if the underlying real-world data wasn't designed to support it.

The organizations closing this gap early aren't choosing between regulatory, clinical, and commercial evidence strategies. They're integrating them from day one, building evidence generation plans that speak the language of every stakeholder across the product lifecycle.

That alignment is what transforms RWE from a checkbox into a driver of market access.

AMCP's Cate Lockhart on why only 18% of payers regularly use real-world evidence, and what the new AMCP RWE Standards are doing to change that.